BioSpace News Archive

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the Company is scheduled to present at two upcoming healthcare investor conferences: Baird 2020 Global Healthcare Conference Date: Thursday, September 10, 2020 Presentation Time: 11:25 a.m. ET Morgan Stanley 18th Annual Global He

AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020.

Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to its senior leadership team. Ed Rebar , Ph.D., joins the company as Chief Technology Officer and Terry Fry , M.D. joins as SVP, Head of T Cell Therapeutics.

NeuroPointDX, a division of Stemina Biomarker Discovery, today announced the appointment of two new board members with extensive experience in the development and commercialization of new molecular diagnostic tests. Barbara Handelin, PhD was founding Director of the DNA Diagnostics Lab at Integrated Genetics (acquired by LabCorp @ $925M), and Tony Shuber was Chief Technology Officer and cofounder of Exact Science Corporati